Mesna — Drug Intelligence | 15 EU Trials

Filter these 15 trials by condition, phase, country and more.

Open in Search →

15 Registered trials

9 Recruiting

5 Completed trials

9 Sponsors

15 Countries

Phase III

Phase II

Phase III: 4 Phase II: 8 Phase IV: 1 Phase I (Other): 1 Phase I (FiH): 1

Oversight events:

15 temporary halts 1 unexpected event 2 corrective measures across 2 trials

View oversight register →

Indications tested

Bladder cancer 1 Neuroblastoma 1 Mantle cell lymphoma refractory 1 Head and neck cancer 1 Testicular seminoma (pure) 1 Germ cell cancer 1 Paraneoplastic neurological syndrome 1

Sponsors using this IMP

Kite Pharma Inc. 6 GPOH gGmbH 2 Assistance Publique Hopitaux De Paris 1 CuraCell Holding AB 1 Institut Gustave Roussy 1 Iovance Biotherapeutics Inc. 1 Turku University Hospital 1 Unicancer 1 University Of Cologne 1

All trials

15 total

Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending

2024-517295-37-00 Phase III 1 country University Of Cologne
Study to investigate lifileucel regimen plus pembrolizumab compared with pembrolizumab alone in participants with untreated, advanced melano… Recruiting

2022-503140-41-00 Phase III 12 countries Iovance Biotherapeutics Inc.
International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and … Recruiting

2024-515245-42-00 Phase I (Other) 4 countries GPOH gGmbH
A First-In-Human, phase I/IIa, open-label trial assessing safety, tolerability, and feasibility of repeated administrations of a novel autol… Recruiting

2025-521227-70-00 Phase I (FiH) 1 country CuraCell Holding AB
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L… Recruiting

2022-501489-24-00 Phase III 7 countries Kite Pharma Inc.
Early immunotherapy with intravenous immunoglobulin, cyclophosphamide and methylprednisolone in patients with anti-Hu-associated paraneoplas… Recruiting

2023-506942-22-01 Phase II 1 country Assistance Publique Hopitaux De Paris
The Effect of Cancer Treatments on Speech Perception in Noise, Cognition, and Quality of Life Recruiting

2024-513437-21-00 Phase IV 1 country Turku University Hospital
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting

2023-505040-19-00 Phase II 1 country Institut Gustave Roussy
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma Recruiting

2022-501180-40-00 Phase III 8 countries GPOH gGmbH
Evaluation of Lymphadenectomy and Chemotherapy TIP (paclitaxel, ifosfamide and cisplatin) on Inguinal Lymph Nodes in Squamous Cell Carcinoma… Recruiting

2024-512827-36-00 Phase II 1 country Unicancer
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501259-10-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501262-21-00 Phase II 7 countries Kite Pharma Inc.
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended

2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.

Showing 1–15 of 15 trials

← All drugs A–Z